Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled maintenance olaparib in newly diagnosed BRCA-mutated advanced ovarian cancer after first-line platinum chemotherapy
MOH_2026-09-16_017039Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Olaparib maintenance with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Nov 2013; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on MOH_2026-09-16_017039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-09-16_017039.